|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
BSEP deficiency leads to severe cholestasis and hepatocellular carcinoma (HCC) in young children.
|
23213087 |
2013 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
MYO5B deficiency appears to impair targeting of BSEP to the canalicular membrane with hampered bile acid excretion, resulting in a spectrum of cholestasis without diarrhea.(Hepatology 2017;65:1655-1669).
|
28027573 |
2017 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Children with normal γ-glutamyltransferase cholestasis (n = 47; 13 patients with ATP8B1 deficiency, 19 with ATP-binding cassette, subfamily B (MDR/TAP), member 11 (ABCB11) deficiency, and 15 without either ATP8B1 or ABCB11 mutations) were enrolled.
|
26382629 |
2015 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
RGD |
Our data suggest that the adenovirus-mediated hepatocyte hAQP1 expression improves LPS-induced cholestasis in rats by stimulating the BSEP/ABCB11-mediated biliary bile acid excretion; a finding that might contribute to the understanding and treatment of sepsis-associated cholestatic diseases.
|
29087027 |
2017 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
GE significantly increased canalicular bile acids secretion via BSEP (P<0.05), subsequently stimulating bile flow during cholestasis.
|
27988401 |
2017 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
BSEP inhibitor drugs produce similar bile salt retention that may lead to severe cholestasis and liver damage.
|
22120137 |
2012 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.
|
11179459 |
2001 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Drug-induced cholestasis is a frequently observed side effect of drugs and is often caused by an unexpected interaction with the bile salt export pump (BSEP/ABCB11).
|
24713091 |
2014 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Endotoxin-induced cholestasis in rodents is caused by hepatic downregulation of transporters, including the basolateral Na+-dependent taurocholate transporter (ntcp) and the canalicular bile salt export pump (bsep) and multidrug resistance-associated protein 2 (mrp2).
|
15205115 |
2004 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
ABCB11 is associated with progressive familial cholestasis.
|
16941683 |
2006 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
CTD_human |
Organic anion transporting polypeptide 1a1 null mice are sensitive to cholestatic liver injury.
|
22461449 |
2012 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The bile salt export pump (BSEP or ABCB11) prevents accumulation of toxic bile salt concentrations in hepatocytes, and BSEP inhibition or deficiency may cause cholestasis and liver injury.
|
23588305 |
2013 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The cholestasis potential of compounds can be determined by specifically investigating the ability to inhibit BSEP-mediated uptake of tauro-nor-THCA-24-DBD, a fluorescent bile salt derivative.
|
31016647 |
2019 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In human, inhibition of BSEP by drugs has been related to drug-induced cholestasis and subsequent cytotoxic effects.
|
24359682 |
2013 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our results suggest that cholestasis in MVID patients results from (1) impairment of the MYO5B/RAB11A apical recycling endosome pathway in hepatocytes, (2) altered targeting of BSEP to the canalicular membrane, and (3) increased ileal BA absorption.
|
24375397 |
2014 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition to familial intrahepatic cholestasis, partial defects in <i>ATP8B1</i>, <i>ABCB11,</i> and <i>ABCB4</i> predispose patients to drug-induced cholestasis and intrahepatic cholestasis in pregnancy.
|
30148122 |
2018 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
One of the major players involved in drug-induced cholestasis is the bile salt efflux pump (BSEP; ABCB11).
|
29309877 |
2018 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Although the exact etiology of cholestasis is incompletely understood, it is hypothesized that ATP8B1 deficiency results in enhanced cholesterol extraction from the canalicular membrane, which impairs the function of the bile salt export pump (BSEP), resulting in cholestasis.
|
20422494 |
2010 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
BSEP deficiency causes cytotoxic accumulation of bile salts in the hepatocyte that results in mild-to-severe forms of cholestasis.
|
28220208 |
2017 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bile salt export pump (BSEP) plays an important role in hepatic secretion of bile acids and its deficiency results in severe cholestasis and liver failure.
|
28150711 |
2017 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this article, we review the potential clinical implications of the major BS transporters BSEP, OSTα/OSTβ and NTCP in the pathogenesis of hereditary and acquired cholestatic syndromes, provide an overview on transcriptional control of these transporters by the key regulatory nuclear receptors and discuss the potential therapeutic role of novel transcriptional activators of BS transporters in cholestasis.
|
24333169 |
2014 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
The most commonly used in vitro models rely on the extent of inhibition of bile salt export pump-mediated taurocholic acid transport, thereby assuming that drug-induced cholestasis mechanisms are merely restricted to the interaction with this sole hepatic transporter.
|
31016665 |
2019 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
RGD |
Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats.
|
12702498 |
2003 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
Decreased function of the bile salt export pump (BSEP) in hepatocytes is suggested to be responsible for the severe cholestasis observed in PFIC1.
|
25022842 |
2014 |
|
Cholestasis
|
0.600 |
Biomarker
|
disease |
BEFREE |
ECL1, a unique domain of BSEP, likely is a critical target involved in transport inhibition as demonstrated in several patients with AIBD manifest as cholestasis.
|
26516723 |
2016 |